All In Biotech

Drug Trial Radar · NCT05552326

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia

Last checked: Nov 20, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 446 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

446

Actual

Start

Aug 31, 2022

Primary completion

Dec 17, 2024

Study completion Sep 12, 2025

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Sep 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

Conditions

  • Severe Hypertriglyceridemia

Interventions

  • OlezarsenDrug

    Olezarsen will be administered by SC injection.

  • PlaceboDrug

    Olezarsen-matching placebo will be administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in Fasting TG Compared to PlaceboTime frame: Baseline and Month 6

Locations

205 sites in 23 countries. Site status is shown where the registry gives one.

  • Central Research Associates, Inc.

    Birmingham, Alabama

  • Alabama Clinical Therapeutics, LLC Alabaster

    Birmingham, Alabama

  • Onyx Clinical Research

    Peoria, Arizona

  • NRC Research Institute

    Los Angeles, California

  • Accel Research Sites

    DeLand, Florida

  • Finlay Medical Research

    Greenacres City, Florida

  • University of Florida Jacksonville

    Jacksonville, Florida

  • Meridien Research

    Maitland, Florida

  • Columbus Clinical Services

    Miami, Florida

  • Harmony Clinical Research, Inc

    North Miami Beach, Florida

  • Combined Research Orlando Phase I-IV

    Orlando, Florida

  • 3Sync Research

    Sunrise, Florida

  • R & B Medical Center LLC

    Tampa, Florida

  • JSV Clinical Research Study, Inc.

    Tampa, Florida

  • Metabolic Research Institute

    West Palm Beach, Florida

  • Emory University

    Atlanta, Georgia

  • Accel Clinical Research

    Eatonton, Georgia

  • Northeast Georgia Medical Center

    Gainesville, Georgia

  • Randomize Now

    Newnan, Georgia

  • St. Vincent Medical Group

    Carmel, Indiana

  • University of Kansas Medical Center (KUMC)

    Kansas City, Kansas

  • The Research Group of Lexington, LLC

    Lexington, Kentucky

  • University of Louisville

    Louisville, Kentucky

  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)

    Louisville, Kentucky

  • Grace Research, LLC

    Bossier City, Louisiana

  • Clinical Trials of America LA, LLC

    Monroe, Louisiana

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • Maryland Cardiovascular Specialists

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Onyx Clinical Research

    Flint, Michigan

  • Onyx Clinical Research

    Rochester Hills, Michigan

  • Stern Cardiovascular

    Southaven, Mississippi

  • NYU Langone Hospital - Long Island

    Mineola, New York

  • Orchard Park Family Practice

    Orchard Park, New York

  • Clinical Trials of America, LLC

    Lenoir, North Carolina

  • Diabetes and Endocrinology Consultants, P.C.

    Morehead City, North Carolina

  • OnSite Clinical Solutions, LLC

    Salisbury, North Carolina

  • The Ohio State University (OSU)

    Columbus, Ohio

  • SV Research LLC

    Marion, Ohio

  • Oklahoma Heart Institute

    Tulsa, Oklahoma

Showing 40 of 205 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.